Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a phase 1, dose-escalating, randomised controlled study

Saye H Khoo, Richard FitzGerald, Thomas Fletcher, Sean Ewings, Thomas Jaki, Rebecca Lyon, Nichola Downs, Lauren Walker, Olana Tansley-Hancock, William Greenhalf, Christie Woods, Helen Reynolds, Ellice Marwood, Pavel Mozgunov, Emily Adams, Katie Bullock, Wayne Holman, Marcin D Bula, Jennifer L Gibney, Geoffrey Saunders, Andrea Corkhill, Colin Hale, Kerensa Thorne, Justin Chiong, Susannah Condie, Henry Pertinez, Wendy Painter, Emma Wrixon, Lucy Johnson, Sara Yeats, Kim Mallard, Mike Radford, Keira Fines, Victoria Shaw, Andrew Owen, David G Lalloo, Michael Jacobs, Gareth Griffiths
doi: https://doi.org/10.1101/2021.05.03.21256309
Saye H Khoo
1University of Liverpool, UK
2Liverpool University Hospital NHS Foundation Trust, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: khoo@liverpool.ac.uk
Richard FitzGerald
2Liverpool University Hospital NHS Foundation Trust, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Fletcher
2Liverpool University Hospital NHS Foundation Trust, UK
3Liverpool School of Tropical Medicine, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sean Ewings
4Southampton Clinical Trials Unit, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Jaki
5University of Lancaster, UK
6MRC Biostatistics Unit, University of Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rebecca Lyon
2Liverpool University Hospital NHS Foundation Trust, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nichola Downs
4Southampton Clinical Trials Unit, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lauren Walker
2Liverpool University Hospital NHS Foundation Trust, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olana Tansley-Hancock
4Southampton Clinical Trials Unit, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William Greenhalf
1University of Liverpool, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christie Woods
2Liverpool University Hospital NHS Foundation Trust, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Helen Reynolds
1University of Liverpool, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ellice Marwood
4Southampton Clinical Trials Unit, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pavel Mozgunov
5University of Lancaster, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emily Adams
3Liverpool School of Tropical Medicine, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katie Bullock
1University of Liverpool, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wayne Holman
7Ridgeback Biotherapeutics, Miami, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marcin D Bula
4Southampton Clinical Trials Unit, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer L Gibney
2Liverpool University Hospital NHS Foundation Trust, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Geoffrey Saunders
4Southampton Clinical Trials Unit, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea Corkhill
4Southampton Clinical Trials Unit, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Colin Hale
2Liverpool University Hospital NHS Foundation Trust, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kerensa Thorne
4Southampton Clinical Trials Unit, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Justin Chiong
1University of Liverpool, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susannah Condie
4Southampton Clinical Trials Unit, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Henry Pertinez
1University of Liverpool, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wendy Painter
7Ridgeback Biotherapeutics, Miami, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emma Wrixon
4Southampton Clinical Trials Unit, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lucy Johnson
4Southampton Clinical Trials Unit, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sara Yeats
4Southampton Clinical Trials Unit, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kim Mallard
4Southampton Clinical Trials Unit, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mike Radford
4Southampton Clinical Trials Unit, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keira Fines
4Southampton Clinical Trials Unit, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Victoria Shaw
1University of Liverpool, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Owen
1University of Liverpool, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David G Lalloo
3Liverpool School of Tropical Medicine, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Jacobs
8Royal Free London NHS Foundation Trust, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gareth Griffiths
4Southampton Clinical Trials Unit, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background AGILE is a phase Ib/IIa platform for rapidly evaluating COVID-19 treatments. In this trial (NCT04746183) we evaluated the safety and optimal dose of molnupiravir in participants with early symptomatic infection.

Methods We undertook a dose-escalating, open-label, randomised-controlled (standard-of-care) Bayesian adaptive phase I trial at the Royal Liverpool and Broadgreen Clinical Research Facility. Participants (adult outpatients with PCR-confirmed SARS-CoV-2 infection within 5 days of symptom onset) were randomised 2:1 in groups of 6 participants to 300mg, 600mg and 800mg doses of molnupiravir orally, twice daily for 5 days or control. A dose was judged unsafe if the probability of 30% or greater dose-limiting toxicity (the primary outcome) over controls was higher than 25%. Secondary outcomes included safety, clinical progression, pharmacokinetics and virologic responses.

Results Of 103 volunteers screened, 18 participants were enrolled between 17 July and 30 October 2020. Molnupiravir was well tolerated at 400, 600 or 800mg doses with no serious or severe adverse events. Overall, 4 of 4 (100%), 4 of 4 (100%) and 1 of 4 (25%) of the participants receiving 300, 600 and 800mg molnupiravir respectively, and 5 of 6 (83%) controls, had at least one adverse event, all of which were mild (≤grade 2). The probability of ≥30% excess toxicity over controls at 800mg was estimated at 0.9%.

Conclusion Molnupiravir was safe and well tolerated; a dose of 800mg twice-daily for 5 days was recommended for Phase II evaluation.

Competing Interest Statement

Potential conflicts of interest. WH is a cofounder, owner and advisor of/to Ridgeback Biotherapeutics LP. WP is employed by Ridgeback Biotherapeutics. Potential conflicts of interest SK has received research funding from ViiV Healthcare, Gilead Sciences, and Merck for the Liverpool HIV Drug Interactions programme and for unrelated clinical studies. Unrelated to the current work, AO is a Director of Tandem Nano Ltd and co-inventor of patents relating to drug delivery. AO has received research funding from ViiV Healthcare, Merck, Janssen and consultancy from Gilead, ViiV and Merck not related to the current work. GG has received funding from Janssen-Cilag, Astra Zeneca, Novartis, Astex, Roche, Heartflow, Celldex, BMS, BionTech, Cancer Research UK, NIHR, British Lung Foundation, Unitaid, GSK for unrelated academic clinical trials and programme funding. WG has received funding from the Wellcome Trust. No conflict. RF, TF, SE, TJ, RL, ND, LW, OTH, CW, HR, EM, PM, EA, KB, MB, JG, GS, AC, CH, KT, JC, SC, HP, EW, LJ, SY, KM, MR, KF, VS, DL, MJ

Clinical Trial

ClinicalTrials.gov Identifier: NCT04746183

Funding Statement

This work was supported by Ridgeback Biotherapeutics. The AGILE platform infrastructure is supported by the Medical Research Council [grant number MR/V028391/1] and the Wellcome Trust [grant number 221590/Z/20/Z].

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study protocol was reviewed and approved by the UK Medicines and Healthcare product Regulatory Agency (MHRA) and West Midlands Edgbaston Research Ethics Committee.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Conflicts of interest Potential conflicts of interest. WH is a cofounder, owner and advisor of/to Ridgeback Biotherapeutics LP. WP is employed by Ridgeback Biotherapeutics.

  • Potential conflicts of interest SK has received research funding from ViiV Healthcare, Gilead Sciences, and Merck for the Liverpool HIV Drug Interactions programme and for unrelated clinical studies. Unrelated to the current work, AO is a Director of Tandem Nano Ltd and co-inventor of patents relating to drug delivery. AO has received research funding from ViiV Healthcare, Merck, Janssen and consultancy from Gilead, ViiV and Merck not related to the current work. GG has received funding from Janssen-Cilag, Astra Zeneca, Novartis, Astex, Roche, Heartflow, Celldex, BMS, BionTech, Cancer Research UK, NIHR, British Lung Foundation, Unitaid, GSK for unrelated academic clinical trials and programme funding. WG has received funding from the Wellcome Trust.

  • No conflict. RF, TF, SE, TJ, RL, ND, LW, OTH, CW, HR, EM, PM, EA, KB, MB, JG, GS, AC, CH, KT, JC, SC, HP, EW, LJ, SY, KM, MR, KF, VS, DL, MJ

  • Funding This work was supported by Ridgeback Biotherapeutics. The AGILE platform infrastructure is supported by the Medical Research Council [grant number MR/V028391/1] and the Wellcome Trust [grant number 221590/Z/20/Z].

Data Availability

The AGILE Trial Steering Committee will consider all reasonable requests by health-care providers, investigators, and researchers to provide anonymised data to address specific scientific or clinical objectives. The AGILE investigators are committed to reviewing requests from researchers for access to clinical trial protocols, de-identified patient-level clinical trial data, and study-level clinical trial data.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted May 05, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a phase 1, dose-escalating, randomised controlled study
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a phase 1, dose-escalating, randomised controlled study
Saye H Khoo, Richard FitzGerald, Thomas Fletcher, Sean Ewings, Thomas Jaki, Rebecca Lyon, Nichola Downs, Lauren Walker, Olana Tansley-Hancock, William Greenhalf, Christie Woods, Helen Reynolds, Ellice Marwood, Pavel Mozgunov, Emily Adams, Katie Bullock, Wayne Holman, Marcin D Bula, Jennifer L Gibney, Geoffrey Saunders, Andrea Corkhill, Colin Hale, Kerensa Thorne, Justin Chiong, Susannah Condie, Henry Pertinez, Wendy Painter, Emma Wrixon, Lucy Johnson, Sara Yeats, Kim Mallard, Mike Radford, Keira Fines, Victoria Shaw, Andrew Owen, David G Lalloo, Michael Jacobs, Gareth Griffiths
medRxiv 2021.05.03.21256309; doi: https://doi.org/10.1101/2021.05.03.21256309
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a phase 1, dose-escalating, randomised controlled study
Saye H Khoo, Richard FitzGerald, Thomas Fletcher, Sean Ewings, Thomas Jaki, Rebecca Lyon, Nichola Downs, Lauren Walker, Olana Tansley-Hancock, William Greenhalf, Christie Woods, Helen Reynolds, Ellice Marwood, Pavel Mozgunov, Emily Adams, Katie Bullock, Wayne Holman, Marcin D Bula, Jennifer L Gibney, Geoffrey Saunders, Andrea Corkhill, Colin Hale, Kerensa Thorne, Justin Chiong, Susannah Condie, Henry Pertinez, Wendy Painter, Emma Wrixon, Lucy Johnson, Sara Yeats, Kim Mallard, Mike Radford, Keira Fines, Victoria Shaw, Andrew Owen, David G Lalloo, Michael Jacobs, Gareth Griffiths
medRxiv 2021.05.03.21256309; doi: https://doi.org/10.1101/2021.05.03.21256309

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Pharmacology and Therapeutics
Subject Areas
All Articles
  • Addiction Medicine (270)
  • Allergy and Immunology (552)
  • Anesthesia (135)
  • Cardiovascular Medicine (1757)
  • Dentistry and Oral Medicine (238)
  • Dermatology (173)
  • Emergency Medicine (312)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (659)
  • Epidemiology (10799)
  • Forensic Medicine (8)
  • Gastroenterology (590)
  • Genetic and Genomic Medicine (2949)
  • Geriatric Medicine (287)
  • Health Economics (534)
  • Health Informatics (1928)
  • Health Policy (836)
  • Health Systems and Quality Improvement (745)
  • Hematology (292)
  • HIV/AIDS (630)
  • Infectious Diseases (except HIV/AIDS) (12517)
  • Intensive Care and Critical Care Medicine (691)
  • Medical Education (299)
  • Medical Ethics (86)
  • Nephrology (324)
  • Neurology (2799)
  • Nursing (151)
  • Nutrition (433)
  • Obstetrics and Gynecology (559)
  • Occupational and Environmental Health (597)
  • Oncology (1466)
  • Ophthalmology (444)
  • Orthopedics (172)
  • Otolaryngology (257)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (381)
  • Pediatrics (866)
  • Pharmacology and Therapeutics (366)
  • Primary Care Research (337)
  • Psychiatry and Clinical Psychology (2640)
  • Public and Global Health (5366)
  • Radiology and Imaging (1013)
  • Rehabilitation Medicine and Physical Therapy (595)
  • Respiratory Medicine (726)
  • Rheumatology (330)
  • Sexual and Reproductive Health (289)
  • Sports Medicine (279)
  • Surgery (327)
  • Toxicology (47)
  • Transplantation (150)
  • Urology (125)